摘要
目的 :探讨DNA拓扑异构酶在卵巢浆液性、黏液性囊腺癌中的表达及与细胞增殖、凋亡的关系。方法 :应用免疫组化S P法检测石蜡包埋的 71例卵巢浆液性、黏液性囊腺癌组织切片中DNA拓扑异构酶Ⅱ (DNAtopoisomeraseⅡ ,TOPOⅡ )表达和细胞增殖指数 (Ki 6 7labelingindex ,Ki 6 7LI)和应用原位末端标记技术 (TUNEL)检测细胞凋亡指数 (apoptosisindex ,AI)。结果 :TOPOⅡ高表达为 36 6 % (2 6 /71) ,与组织学类型、FIGO分期和组织学分级差异无显著性 (P >0 0 5 ) ;Ki 6 7LI高表达为 43 7% (31/71) ,与FIGO分期差异有显著性 (P <0 0 0 1) ;AI高表达为 2 5 6 % (18/71) ,与组织学分级、FIGO分期和组织学分级均差异无显著性 (P >0 0 5 ) ,但AI与TOPOⅡ表达有相关 (P <0 0 1)。结论 :应用免疫组化方法检测组织中TOPOⅡ和Ki 6 7LI水平 ,对卵巢浆液性。
Purpose To investigate the relationship between DNA topoisomerase and cell proliferation, apoptosis in ovarian carcinomas. Methods Seventy one patients with histologically proven ovarian carcinomas were selected. The Ki 67 labeling index (Ki 67 LI ) and DNA topoisomerase Ⅱ (TOPOⅡ) were stained by MIB 1 and by SWT3D1 monoclonal antibodies using immunohistochemical method. The apoptotic index ( AI ) by the terminal deoxynucleotidyl transterase mediated dUTP biotin nick end labeling (TUNEL) technique on serial sections of formalin fixed and paraffin embedded tissues. Results Overexpression of TOPOⅡ was 36 6%(26/71) and no correlation was found with histologic types, FIGO stage and histological grading in ovarian carcinoma. Ki 67 LI was found significantly different ( P <0 001) in FIGO stage. Correlation was not observed between AI and histologic types, FIGO stage and histological grading. But AI was positively related with TOPOⅡ expression. Conclusion Status of TOPOⅡ and Ki 67 detected by immunohistochemistry is a useful predictor for clinical chemotherapy and for prognosis in ovarian carcinomas.
出处
《临床与实验病理学杂志》
CAS
CSCD
2001年第4期286-289,共4页
Chinese Journal of Clinical and Experimental Pathology
